„Ensuring Regulatory and Pharmacovigilance Compliance“ „Ensuring Regulatory and Pharmacovigilance Compliance“

Slides:



Advertisements
Similar presentations
Project Quality Plans Gillian Sandilands Director of Quality
Advertisements

Overview of Risk management: A EU perspective Lincoln Tsang May 2008.
The Information Professionals Role in Product Safety Jack Leitmeyer Director, Adverse Experience Information Management Worldwide Product Safety Merck.
Tips to a Successful Monitoring Visit
Pharmacovigilance by Dr. Notghi Contract Research.
The Principal Investigator’s Roles and Responsibilities Chicken Soup for the Busy Coordinator (May 2010)
Safety Reporting IN Clinical Trials
„Ensuring Regulatory and Pharmacovigilance Compliance“ „Ensuring Regulatory and Pharmacovigilance Compliance“
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Managing Sponsorship Research Services University of Oxford.
Research Ethics-Integrity-Governance. University Initiative:The Catalyst? ‘02 Good Research Practice Standards & Procedure to Investigate Potential Research.
Your global support in Europe Over 20 years of experience ELM Pharmaceutica.
ELM Farmacéutica. MEDICINAL PRODUCTS From development to marketing Development Dossier in European form Marketing authorization in UE Marketing Meetings.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
Good Clinical Practice GCP
Healing Hands Clinical Research Services is a Site Management organization with broad spectrum of activities.
GIQAR Annual Congress 25 – 26 th May Pv QA: Quality Assurance for Pharmacovigilance Allison Jack Manager, R&D Oversight – GCP/PV, Pfizer Ltd BARQA.
IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.
Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
„Ensuring Regulatory and Pharmacovigilance Compliance“ „Ensuring Regulatory and Pharmacovigilance Compliance“
Pharmacovigilance obligations of the Pharmaceutical companies in India
A M I L C A R AMI LCA R Advice in Medical Investigation and Logistics for Communication And Research The Universitary-linked.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
Role of the Oncology Research Team Carmen B. Jacobs, RN, OCN, CCRP.
INTRODUCTION TO RA.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
SIPLAS RO is a full service contract research organization CRO, offering nanotechnology, biopharmaceutical and medical device companies comprehensive.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
MEDICAL experts INDUSTRY Some of our clients. Pharmaceutical companies, manufacturers of medical and surgical devices, clinical research organizations,
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
ACCREDITED CONSULTANTS PVT LTD. (ACPL) WELCOMES YOU Your PHARMACOVIGILANCE PARTNER.
R&D – a perspective Dr Nana Theodorou Research Coordinator Sheffield Clinical Research Office.
Development and Approval of Drugs and Devices EPI260 Lecture 6: Late Phase Clinical Trials April 28, 2011 Richard Chin, M.D.
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
Agenda for Session Compliance in Clinical Research
Good Clinical Practice (GCP) UKTMN 6 th June 2006.
PharmacoVigilance: Development of PhV systems and processes.
THE OFFICE FOR REGISTRATION OF MEDICINAL PRODUCTS, MEDICAL DEVICES AND BIOCIDAL PRODUCTS Responsibility in the handling of medical devices.
1 Division of Pharmacoepidemiology and Pharmacovigilance AEMPS Dolores Montero Corominas 20 November Management of the Adverse drug reaction (ADR),
Quality Metrics of Performance of Research Ethics Committees Cristina E. Torres, PhD FERCAP Coordinator.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
2009 DIA US Annual Meeting GCP Session Advisory Committee Meeting
RAC Regulatory Affairs Certification
Off-label Use.
A capacity building programme for patient representatives
Responsibilities of Sponsor, Investigator and Monitor
2009 DIA US Annual Meeting GCP Session Advisory Committee Meeting
Regulation EU 536/2014 on clinical trials
The Information Professional’s Role in Product Safety
Risk Communication in Medicines
EudraVigilance.
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Good Clinical Practice
Pharmacovigilance in clinical trials
TAIEX, Istanbul, April 19th, 2011
MAH Responsibilities and the Role of the QP
Pharmacovigilance updates
Pharmacovigilance inspections: what HPRA expects
Code of Ethics for CDM Professionals
Code of Ethics for CDM Professionals
Presentation transcript:

„Ensuring Regulatory and Pharmacovigilance Compliance“ „Ensuring Regulatory and Pharmacovigilance Compliance“

„Ensuring Regulatory and Pharmacovigilance Compliance“ Team of specialised experts All services for whole Europe in one place EU regulatory knowledge and strategies MA holding and support EU/local RA and PHV contact Who we are?

„Ensuring Regulatory and Pharmacovigilance Compliance“ Our Services Continuous support and updates depending on EU legislation Regulatory services - Medicinal products, medical devices - Cosmetics, food supplements - Veterinary products Education + trainings Clinical Trials PASS - Post-Authorisation Safety Studies Marketing + sales - Import/Distribution - Marketing

„Ensuring Regulatory and Pharmacovigilance Compliance“ Our Services – Key Features Partner/Products/Concept analysis - Identification of key issues and risks of market entry - Elaborating of possible scenarios and strategy alternatives Quantification of the alternatives - Value, Time, Risks Evaluation of the influence on - Product definition - Registration strategy - Pricing - Reimbursement - Follow up procedures

„Ensuring Regulatory and Pharmacovigilance Compliance“ Scope of The Services in Regulatory Affairs Consultation and registration services in the territories - EU countries - Croatia - Russian - Ukraine Strategy, Registration, Maintenance Services in - Human and veterinary medicinal products - All alternatives of registration procedures (National, CP, MRP, DCP) - Food supplements and novel foods - Medical equipments/devices - „Health“ Cosmetics

„Ensuring Regulatory and Pharmacovigilance Compliance“ Registration Files - Submissions –Compilation and evaluation –Completeness and quality check: pre-submission –Preparation of CTD files –Support in creating Module 1 for all procedures according national/EU requirements –Negotiations with authorities –DCP slots blocking and management –Transforming/ creating of e-CTD format

„Ensuring Regulatory and Pharmacovigilance Compliance“ e - CTD The electronic Common Technical Document (e-CTD) is an interface for the pharmaceutical industry to agency transfer of regulatory information. The content is based on the Common Technical Document (CTD) format. The e-CTD was developed by the ICH as standard format for regulatory submissions in the Europe, USA and Japan.

„Ensuring Regulatory and Pharmacovigilance Compliance“ Registration Files - Text Management Compliant in each country Insert leaflet, summary of product characteristic (PIL), packaging material (mock-ups) Harmonization of texts according to: –Actual QRD format –Local requirements –EU reference product (generics) Mock-up creation Translation of texts to all languages Braille requirements The smooth pass of the texts → fundamental part of instant national phase of registration → fundamental part of instant national phase of registration

„Ensuring Regulatory and Pharmacovigilance Compliance“ Complex Regulatory Maintenance Management Variations Communication with authorities Renewals of MAs Sunset clause monitoring and solving Professional maintenance management → saved time, stress, money …

„Ensuring Regulatory and Pharmacovigilance Compliance“ Pharmacovigilance Pharmacovigilance monitoring of the products 24/7/365 - Non-stop services for receipt of adverse events signals - Proprietary PHV database - Literature search service - Safety studies /clinical trials support Complex services of QPPV: - Creation and run of the PHV system according to current EU requirements - Electronic submission of ADRs/AEs to EMA/NA (MedDRA, EudraVig) - Compulsory regular PHV training of the stuff - Electronic submission of product information to EMA database (XEVMPD)

„Ensuring Regulatory and Pharmacovigilance Compliance“ Other Services Public information service - 24/7/365 patient service - Disabled people Consultation services for - Patients - Health care professionals - Companies The role of Pharmacovigilance is becoming extremely important part of the daily business

„Ensuring Regulatory and Pharmacovigilance Compliance“ Clinical Trials

„Ensuring Regulatory and Pharmacovigilance Compliance“ Clinical Trial Preparation Feasibility studies, start-up support Selection of qualified investigators and trial sites Preparation of study documents (Protocol, Investigator´s Brochures, Informed Consent Form, questionnaires, manuals etc.) Protocol and medical writing Statistical support, clinical trial designing Submission to regulatory authorities and ethics committees Co-ordination of preparation works, investigator´s meeting

„Ensuring Regulatory and Pharmacovigilance Compliance“ Monitoring and CT Management Site management, communication with investigators, on- site activities Trial monitoring in compliance with Good Clinical Practice (GCP) Data management and statistical data processing Identification of changes and evaluation of regulatory aspects Supervision of the progress of a clinical trial Support for fast recruitment Ensuring protocol compliance Applying SOPs, GCP and applicable regulatory requirements Set up of adequate procedures for quality control and quality assurance

„Ensuring Regulatory and Pharmacovigilance Compliance“ Medical Services Support of the investigators Preparation of Standard Operating Procedures Good Clinical Practice trainings Good Laboratory Practice trainings Good Manufacturing Practice for Advanced Therapies Legal aspects of CT, data protection, insurance Medical Services Medical support of project teams 24/7 medical support, ongoing medical safety review Medical review of clinical study reports Medical expert opinion Medical reporting (Interim, final reports, safety reports)

„Ensuring Regulatory and Pharmacovigilance Compliance“ Pharmacovigilance, Risk Management QPPV service Immediate report of serious adverse events to the sponsor Reporting of SUSARS and all safety issues to the authorities and ethics committee Submission of annual safety reports to the competent authority and the ethics committee Transmission of safety reports to the investigators Immediate hazard management Risk management plan Continuous follow-up and evaluation of risks Quality assurance and Quality Control, QA/QC Audits

„Ensuring Regulatory and Pharmacovigilance Compliance“ PASS

„Ensuring Regulatory and Pharmacovigilance Compliance“ Post-Authorisation Safety Studies (PASS) A post-authorisation safety study (PASS) is defined in Article 1(15) of Directive 2001/83/EC as any study relating to an authorised medicinal product conducted with the aim of identifying, characterising or quantifying a safety hazard, confirming the safety profile of the medicinal product, or of measuring the effectiveness of risk-management measures. PASS are designed to ensure that medicinal products are monitored for long-term safety and effectiveness in Routine Clinical Practice and may be initiated, managed or financed by MAH voluntarily, or pursuant to an obligation imposed by a competent authority. PASS – Critical New Tool in searching for „Missing Information“

„Ensuring Regulatory and Pharmacovigilance Compliance“ PASS - Services PASS Management Definition of scientific format of protocols, abstracts and final study report for non-interventional PASS Identification of the Requirements and Key elements for PASS Creating Guidance on Effectiveness of Risk Minimisation Establishing monitoring system – GVP (Good Pharmacovigilance Practice) E-register of non-interventional PASS maintained by the Agency Publication of Final Study Report PASS On-site services ON-SITE preparation of PASS (including on-site training, contract issue etc.) ON-SITE Data Management and Data Collection of PASS e-CRFs services, Statistical analysis Preparing FINAL Study Report

„Ensuring Regulatory and Pharmacovigilance Compliance“ Education & Training

„Ensuring Regulatory and Pharmacovigilance Compliance“ Education & Training Regulatory affairs excellence is mainly driven by knowledge – let´s be up to date and learn effectively Life Cycle of Medicinal Products Biostatistics GCP course Coordination of the clinical trials All courses are provided in co-operation with PharmAround education platform

„Ensuring Regulatory and Pharmacovigilance Compliance“ Marketing + Sales

„Ensuring Regulatory and Pharmacovigilance Compliance“ Market Access Market analysis and market environment Market Access strategy – reflecting actual and upcoming legislation development and „current“ practices Pharmacoeconomic analysis - Budget impact - Cost effectiveness - Cost containment….. Preparement and submission of application for - Maximum price - Reimbursement Organisation of „patient registries“ Management of „life cycle“ of the reimbursement/price

„Ensuring Regulatory and Pharmacovigilance Compliance“ Regulatory House – „All you need“

„Ensuring Regulatory and Pharmacovigilance Compliance“ e- mail: Skype: regulatory.house